AAIP logo

Moderna to Request FDA Authorization of a COVID-19 Vaccine for Children 6 months to Under 6 years

The request is based on interim data from the Phase 2/3 KidCOVE study of a 25 µg two-dose mRNA vaccine.

Moderna found that these doses “showed a robust neutralizing antibody response” similar to adults’ doses, with a “favorable safety profile.”

Click here to learn more.

Skip to content